Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Tvardi Therapeutics, Inc. (TVRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TVRD (1-star) is a SELL. SELL since 3 days. Simulated Profits (-77.10%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $56.2
1 Year Target Price $56.2
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.82% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.26M USD | Price to earnings Ratio - | 1Y Target Price 56.2 |
Price to earnings Ratio - | 1Y Target Price 56.2 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 5.65 - 43.65 | Updated Date 09/28/2025 |
52 Weeks Range 5.65 - 43.65 | Updated Date 09/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 221232847 | Price to Sales(TTM) - |
Enterprise Value 221232847 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9360900 | Shares Floating - |
Shares Outstanding 9360900 | Shares Floating - | ||
Percent Insiders 27.53 | Percent Institutions 2.76 |
Upturn AI SWOT
Tvardi Therapeutics, Inc.
Company Overview
History and Background
Tvardi Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing STAT3 inhibitors for the treatment of cancer and fibrosis. Founded in 2017, it is based in Houston, Texas. The company's focus is on small molecule inhibitors of STAT3, a transcription factor implicated in a variety of diseases.
Core Business Areas
- Drug Development: Focuses on developing small molecule inhibitors of STAT3 for cancer and fibrosis.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Development: Continues to research and discover new STAT3 inhibitors and their potential applications.
Leadership and Structure
Tvardi is led by a team of experienced biotechnology executives and scientists. The company has a typical organizational structure for a biotech company, with departments dedicated to research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Tvardi's STAT3 Inhibitors: Tvardi's primary focus is on developing small molecule inhibitors of STAT3. Their lead drug candidate is TTI-101, an orally bioavailable small molecule STAT3 inhibitor. Currently, they do not have market share as they are still developing their drug candidates. Competitors include companies targeting similar pathways or cancers through other mechanisms, like targeted therapies and immunotherapies. Companies like Bristol Myers Squibb (BMY), Merck (MRK), and Roche (RHHBY) are competitors in the broader cancer treatment market.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and innovative, with companies constantly seeking to develop new and improved treatments for various diseases. The market for cancer and fibrosis treatments is substantial and growing, driven by aging populations and increasing disease prevalence.
Positioning
Tvardi is positioned as a developer of novel STAT3 inhibitors, targeting a pathway with broad implications in cancer and fibrosis. Its competitive advantage lies in its potentially first-in-class approach with its specific STAT3 inhibition technology.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be hundreds of billions of dollars. Tvardi is positioned to capture a segment of this market by focusing on STAT3 inhibition in specific cancer subtypes and fibrotic diseases.
Upturn SWOT Analysis
Strengths
- Novel STAT3 inhibition technology
- Experienced leadership team
- Strong intellectual property position
- Focus on unmet medical needs
Weaknesses
- Early-stage development company
- High cash burn rate
- Reliance on clinical trial success
- Private company, less financial transparency
Opportunities
- Potential for breakthrough therapies
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new indications
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- RHHBY
Competitive Landscape
Tvardi has the advantage of the first-in-class potential of STAT3 inhibitors. However, it is at a disadvantage due to the large amount of resources that other large competitors have.
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future growth depends on clinical trial outcomes and potential partnerships. Analyst estimates are not publicly available for private companies.
Recent Initiatives: Recent initiatives include advancing TTI-101 through clinical trials and exploring new indications for its STAT3 inhibitors.
Summary
Tvardi Therapeutics is a clinical-stage company with potential in STAT3 inhibition. Its strength lies in its innovative approach, but its reliance on clinical trial success and funding is a risk. Strategic partnerships and successful clinical outcomes are crucial for the company's growth, needing to watch out for clinical failure and regulatory hurdles. The company needs to improve on brand awareness and find more channels to publicise the work they are doing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Industry News Reports
- Market Analysis Reports
Disclaimers:
This analysis is based on publicly available information and estimates, and should not be considered financial advice. Market share data is approximate and may vary. All investment decisions should be made with the assistance of a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tvardi Therapeutics, Inc.
Exchange NASDAQ | Headquaters Sugar Land, TX, United States | ||
IPO Launch date 2014-01-31 | CEO & Director Dr. Imran Alibhai Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://tvarditherapeutics.com |
Full time employees 11 | Website https://tvarditherapeutics.com | ||
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.